VVP
VNDA icon

Venture Visionary Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

Venture Visionary Partners’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-256
Closed -$2.79K – 1510
2022
Q2 		$2.79K Buy
+256
New +$2.65K ﹤0.01% 1502

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Venture Visionary Partners's VNDA Position: Q3 2022 in Review

Venture Visionary Partners sold out of Vanda Pharmaceuticals (VNDA) in Q3 2022, closing a stake of 256 shares — an estimated $2.79K sold.

Venture Visionary Partners first reported a position in VNDA in Q2 2022 and held it in 1 quarter. The position peaked at $2.79K in Q2 2022. 178 funds tracked by Wall St. Rank hold VNDA as of Q3 2022.

  • Venture Visionary Partners reported no remaining Vanda Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Venture Visionary Partners sold 256 Vanda Pharmaceuticals shares in Q3 2022, an estimated $2.79K.
  • Venture Visionary Partners first reported a position in Vanda Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Venture Visionary Partners's Vanda Pharmaceuticals position peaked at $2.79K in Q2 2022.
  • 178 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2022.

Based on Venture Visionary Partners's 13F filing for Q3 2022, filed 14 Nov 2022.